Publication: Drug Discovery and Development

First reported 18 mins ago - Updated 18 mins ago - 1 reports

Small Molecule Shows Potential in Advanced Cancers

Cleveland BioLabs Inc. announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule. The study was performed in patients with advanced cancers for which no standard care exists ... [Published Drug Discovery and Development - 18 mins ago]
First reported 18 mins ago - Updated 18 mins ago - 1 reports

Phase 1 Results Positive for Tumor Vaccine

Celldex Therapeutics Inc. announced that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine . The data demonstrate robust antibody and T cell responses ... [Published Drug Discovery and Development - 18 mins ago]
First reported 4 hours ago - Updated 4 hours ago - 1 reports

Drug Developers Using New Models, Methods to Boost Clinical Success Rates

Drug companies and their development partners who are seeking to increase clinical success rates of new drug candidates are developing tools to help them predict the likelihood of marketing approval and incorporating business planning earlier in clinical ... [Published Drug Discovery and Development - 4 hours ago]
First reported 23 hours ago - Updated 9 hours ago - 1 reports

AbbVie’s Lung Cancer Drug Advances to Phase 3

AbbVie announced the initiation of a global Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung ... [Published Drug Discovery and Development - 23 hours ago]
First reported Apr 15 2014 - Updated 17 hours ago - 1 reports

FDA OKs Trials for Vivolux First-in-Class Cancer Drug

Vivolux AB, a drug discovery company specialized in cancer treatment, announced that the FDA has granted clearance to proceed with VLX600 into clinical Phase 1/2 trials. VLX600, one of the company's promising projects, was the subject of a study recently ... [Published Drug Discovery and Development - Apr 15 2014]
First reported 23 hours ago - Updated 23 hours ago - 1 reports

2014 R&D 100 Awards Entry Deadline Extended

The editors of R&D Magazine have announced that there is still plenty time to prepare your Entry Form for the 2014 R&D 100 Awards. In addition to a shorter, simpler form this year, the editors have decided to give participants an extra two weeks to prepare ... [Published Drug Discovery and Development - 23 hours ago]
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

FDA Accepts BI, Lilly NDA for Type 2 Diabetes Combo Tablet

Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. announced the U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin for ... [Published Drug Discovery and Development - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

Abbvie’s Ribavirin Promising for Hep C Patients with Liver Cirrhosis

AbbVie announced that new, detailed results from its hepatitis C development program were presented Saturday at the International Liver Congress (ILC) 2014. Data from a pivotal Phase 3 study, TURQUOISE-II, featured in the ILC press conference on Saturday, ... [Published Drug Discovery and Development - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

Astellas European Foundation Awards 2014 Urology Grant

The Astellas European Foundation announced the recipient of the 2014 Functional Urology and Uro-Gynecology Grant as Dr. Marianne Gamper for a project to be undertaken jointly in Austria and Switzerland to quantify marker levels to identify the potential ... [Published Drug Discovery and Development - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 15 2014 - 1 reports

Ex Vivo Data Supports Mast's Sickle Cell Treatment

Mast Therapeutics Inc. announced that, in an ex vivo study conducted at Loyola University Medical Center, MST-188 reduced the mean erythrocyte sedimentation rate (ESR) by 50% relative to control in blood collected from individuals with sickle cell disease. ... [Published Drug Discovery and Development - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Janssen Posts Final Data from Phase 2 COSMOS Study

Janssen R&D Ireland announced new results from cohort 2 of the Phase 2 COSMOS study demonstrating that 93% of patients with the hepatitis C virus (HCV) and advanced liver fibrosis (METAVIR scores F3 and F4) who were treated with simeprevir administered ... [Published Drug Discovery and Development - Apr 14 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 1 reports

Collaboration Advances Use of Antibody Drug Conjugates

PolyTherics Ltd., a provider of technologies and services to enable the development of better biopharmaceuticals, announced an extension to its ThioBridge antibody drug conjugate (ADC) collaboration with MacroGenics Inc., a U.S. biotechnology company ... [Published Drug Discovery and Development - Apr 11 2014]

Quotes

Thomas Davis, Senior Vice President and Chief Medical Officer of Celldex Therapeutics added, "CDX-1401 has overcome a significant historical challenge in the development of protein based vaccines by successfully targeting dendritic cells in vivo. It now sits at the forefront of a new generation of off-the-shelf dendritic cell targeted vaccines that we believe hold significant promise. Based on the results observed in this Phase 1 study, we expect CDX-1401 to enter at least two combination studies this year with both our own investigational therapies and external therapies in melanoma and other indications where we believe a dendritic cell vaccine regimen could play an important role." Initial results from the Phase 1 study of CDX-1401 were presented at the 2012 Society for Immunotherapy Annual Meeting...
Andrey Leonov, chief executive officer of Incuron said, "We are very encouraged by the outcome of this trial. We are looking to partner CBL0102 for further potential development, as well as support investigator-initiated trials. Moreover, the information derived from this trial of CBL0102 supports the development of our optimized proprietary FACT inhibitor, CBL0137, which is currently being evaluated in the United States and in Russia in ongoing Phase 1 trials assessing both oral and intravenous administration."
...particularly when it is diagnosed in the more advanced stages of the disease," said Scott Brun, vice president, Pharmaceutical Development, AbbVie. "This PhasePhase 3 trial is an important step in the development of veliparib and in potentially providing patients with squamous non-small cell lung cancer with a new treatment option."
Stig Linder, professor of experimental oncology at the Karolinska Institute and the person who has led the development work, said: "VLX600 has killed colon cancer cells found deep inside solid tumors in various in vitro and in vivo models. These tumor cells are difficult to access by conventional chemotherapy. The therapeutic effect of VLX600 relies on the vulnerability of malignant cells in the deep tumor parenchyme to disturbances of energy supplies. It is truly exciting that our research may help cancer patients in the forthcoming clinical studies."

More Content

All (127) | News (127) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Phase 1 Results Positive for Tumor Vaccine [Published Drug Discovery and Development - 18 mins ago]
Small Molecule Shows Potential in Advanced Cancers [Published Drug Discovery and Development - 18 mins ago]
Drug Developers Using New Models, Methods to Bo... [Published Drug Discovery and Development - 4 hours ago]
AbbVie’s Lung Cancer Drug Advances to Phase 3 [Published Drug Discovery and Development - 23 hours ago]
2014 R&D 100 Awards Entry Deadline Extended [Published Drug Discovery and Development - 23 hours ago]
FDA OKs Trials for Vivolux First-in-Class Cance... [Published Drug Discovery and Development - Apr 15 2014]
Ex Vivo Data Supports Mast's Sickle Cell Treatment [Published Drug Discovery and Development - Apr 14 2014]
FDA Accepts BI, Lilly NDA for Type 2 Diabetes C... [Published Drug Discovery and Development - Apr 14 2014]
Janssen Posts Final Data from Phase 2 COSMOS Study [Published Drug Discovery and Development - Apr 14 2014]
Astellas European Foundation Awards 2014 Urolog... [Published Drug Discovery and Development - Apr 14 2014]
Abbvie’s Ribavirin Promising for Hep C Patients... [Published Drug Discovery and Development - Apr 14 2014]
After Setback, Impax Resubmits Parkinson’s NDA [Published Drug Discovery and Development - Apr 11 2014]
Collaboration Advances Use of Antibody Drug Con... [Published Drug Discovery and Development - Apr 11 2014]
AbbVie's Hep C Regimen Posts Promising Phase 3 ... [Published Drug Discovery and Development - Apr 11 2014]
Affimed’s Lymphoma Drug Shows Favorable Safety ... [Published Drug Discovery and Development - Apr 10 2014]
Tocagen Reports Positive Trial Results for Brai... [Published Drug Discovery and Development - Apr 10 2014]
Gilead Posts Positive Results for All-Oral Sofo... [Published Drug Discovery and Development - Apr 10 2014]
Hemophilia Drug Maintains Low Bleeding Rates in... [Published Drug Discovery and Development - Apr 10 2014]
AbbVie's New Advanced Parkinson's Treatment Ava... [Published Drug Discovery and Development - Apr 10 2014]
FDA Stops Halozyme PEGPH20 Pancreatic Cancer Trial [Published Drug Discovery and Development - Apr 09 2014]
Phase 2 Efatutazone Trial Shows Challenge of Ma... [Published Drug Discovery and Development - Apr 09 2014]
FDA Wants More Info on Forest’s COPD Drug [Published Drug Discovery and Development - Apr 09 2014]
Faking Fluorescence [Published Drug Discovery and Development - Apr 09 2014]
Roche Snags New Biopharma Company for Antibioti... [Published Drug Discovery and Development - Apr 09 2014]
Glucosamine Promotes Longevity in Mice [Published Drug Discovery and Development - Apr 09 2014]
Pharmacyclics Files Imbruvica Supplemental NDA [Published Drug Discovery and Development - Apr 08 2014]
Calithera Glutaminase Inhibition Assay Shows Pr... [Published Drug Discovery and Development - Apr 08 2014]
Minitron Incubator Shaker - Maximum Performance... [Published Drug Discovery and Development - Apr 08 2014]
EU Approves Two-Dose Gardasil for Early Teens [Published Drug Discovery and Development - Apr 08 2014]
Merck Serono Begins Phase 3 NSCLC Trial of Tece... [Published Drug Discovery and Development - Apr 08 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.